GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE(TM) Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021
Stock Information for GT Biopharma Inc.
Loading
Please wait while we load your information from QuoteMedia.